Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
Alcaide
M L
ML
Kolber
M
M
Jayaweera
D
D
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir
D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine